Avenue Therapeutics appoints David Jin as Interim Principal Financial Officer

AVENUE THERAPEUTICS, INC.

David Jin, 32, appointed Interim Principal Financial Officer effective May 11, 2022.
Jin also serves as Interim Principal Executive Officer and Chief Operating Officer.
Jin is VP of Corporate Development at Fortress Biotech; prior roles include Barings, Sorrento Therapeutics, FBR & Co, IMS Health.
No family relationships with directors or executive officers; no reportable transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

David Jin

Interim Principal Financial Officer

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2022-05-11
Filed: May 13, 2022, 7:59 PM ET

On May 11, 2022, Avenue Therapeutics, Inc. (the “Company”) appointed David Jin as the Company’s Interim Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Jin was appointed as Interim Principal Financial Officer at AVENUE THERAPEUTICS, INC..

Action: appointed
Role: Interim Principal Financial Officer

Exact text from the filing

On May 11, 2022, Avenue Therapeutics, Inc. (the “Company”) appointed David Jin as the Company’s Interim Principal Financial Officer.

View on SEC.gov

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-060416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.